First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients (TEAMS)
Topiramate in the Treatment of Epilepsy: 1st Add-on vs. Mono-therapy Study in Neuro-Surgical Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be diagnosed with seizure disorder
- Have been receiving concomitant therapy with one antiepileptic drug (AED), at stable dose prior to trial entry
- Must be dissatisfied with the current treatment
Exclusion Criteria:
- Have treatable cause of seizures (eg, metabolic disturbance, toxic exposure, an active infection, or neoplasm)
- Have grade IV astrocytomas, eg, Glioblastoma multiforme (GBM) or metastases with progression
- Have seizures occurring only in clustered patterns defined as numerous seizures occurring in less than 30 min
- Have had history (within past six months) of a psychiatric or mood disorder requiring electroconvulsive therapy, major tranquilizers, or monoamine oxidase inhibitors
- Have had schizophrenic or history of exhibiting psychotic symptomatology
- Inability to take medication or maintain a seizure calendar, independently or with assistance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Topiramate add-on therapy
|
Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.
|
|
Experimental: Topiramate monotherapy
|
Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Seizure Free Rate: Percentage of Participants Who Did Not Have Any Seizure Episode Within the Last Month of the Maintenance Period (ie, Month 4).
Time Frame: Month 4
|
Month 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Seizure Frequency: Percent Change of Seizure Frequency by the ANCOVA Model During the Month 4
Time Frame: Baseline (4 weeks retrospective assessment prior to start of titration period) to Month 4
|
Seizure frequency (seizure count/month) was calculated based on the number of seizure within a month.
The mean seizure frequency analyzed by the ANCOVA model at each period.
|
Baseline (4 weeks retrospective assessment prior to start of titration period) to Month 4
|
|
Dosage Administration of Topamax During Month 4
Time Frame: Month 4
|
Month 4
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Janssen-Cilag Taiwan Clinical Trial, Janssen-Cilag Taiwan
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR017248
- TOPMATEPY4061 (Other Identifier: Janssen-Cilag Taiwan)
- TOP-TWN-MA4 (Other Identifier: Janssen-Cilag Taiwan)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.